Saguaro Biosciences Secures $3M Seed Funding to Expand AI-Enhanced Cell Analysis Tools
Saguaro Biosciences is at the forefront of integrating artificial intelligence with biotechnological research to create innovative solutions that push the boundaries of life sciences.
Company Name: Saguaro Biosciences
Location: Quebec City, Canada
Sector: Biotechnology, Artificial Intelligence
Funding Details: Raised $3M in Seed funding. The round was led by AQC Capital and Anges Québec, with participation from Martin Leblanc, Co-Founder and Vice-Chairman of CellCarta Biosciences, and investments from Investissement Quebec and Ville de Québec.
Purpose of Investment: To drive the commercial expansion of ChromaLive™, a reagent platform that enhances time-sensitive imaging and AI-enabled analysis of cells.
Leadership: Led by CEO Louis Turcotte.
Product: ChromaLive™, the flagship product of Saguaro Biosciences, is a live cell reagent platform designed to enable advanced cell imaging and analysis. This platform equips researchers with the necessary tools to conduct AI-enhanced discoveries in cell biology, facilitating faster and more accurate analysis that can lead to breakthroughs in medical research and drug development.
About Company: Saguaro Biosciences is at the forefront of integrating artificial intelligence with biotechnological research to create innovative solutions that push the boundaries of life sciences. The company’s mission is to provide researchers worldwide with cutting-edge tools that simplify complex biological data, thereby accelerating scientific discoveries and the development of new therapies.
Impact: The funding will support Saguaro Biosciences in scaling the reach of ChromaLive™, promoting its adoption across more research institutions and pharmaceutical companies. It will also enable the company to enhance its product offerings, potentially leading to groundbreaking applications in health and medicine.